U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen

Reuters12-11
U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen

Dec 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ICU Medical, Lennar Corp and Sweetgreen on Wednesday.

HIGHLIGHTS

* Dave & Buster'S Entertainment Inc PLAY.O: Gordon Haskett cuts to hold from buy

* ICU Medical Inc ICUI.O: Jefferies raises to buy from hold

* Lennar Corp LEN.N: Barclays cuts to equalweight from overweight

* Sweetgreen Inc SG.N: KeyBanc initiates coverage with sector weight rating

* Taylor Morrison Home Corp TMHC.N: Barclays raises to overweight from equalweight

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Acelyrin Inc SLRN.O: Jefferies cuts target price to $8 from $14

* Alaska Air Group Inc ALK.N: JP Morgan raises target price to $85 from $58

* Arthur J. Gallagher & Co. AJG.N: KBW raises target price to $292 from $260

* Aspen Technology Inc AZPN.O: Baird raises target price to $275 from $250

* Dave & Buster'S Entertainment Inc PLAY.O: Gordon Haskett cuts to hold from buy

* Dave & Buster'S Entertainment Inc PLAY.O: Gordon Haskett cuts PT to $34 from $40

* DR Horton Inc DHI.N: Barclays cuts to equalweight from overweight; cuts PT to $170 from $192

* Epam Systems Inc EPAM.N: Jefferies raises target price to $305 from $270

* Ferguson FERG.N: Berenberg raises target price to $240 from $224

* GE Vernova Inc GEV.N: JP Morgan raises target price to $367 from $356

* ICU Medical Inc ICUI.O: Jefferies raises to buy from hold

* IQVIA Holdings Inc IQV.N: Baird cuts target price to $212 from $213

* KB Home KBH.N: Barclays cuts to equalweight from overweight; cuts target price to $85 from $99

* Kenvue Inc KVUE.N: HSBC raises target price to $23 from $21

* Lennar Corp LEN.N: Barclays cuts to equalweight from overweight

* Lennar Corp LEN.N: Barclays cuts target price to $181 from $210

* Mediaalpha Inc MAX.N: KBW cuts target price to $22 from $26

* Nike Inc NKE.N: Barclays cuts target price to $79 from $81

* Ollie'S Bargain Outlet Holdings OLLI.O: Piper Sandler raises target price to $126 from $107

* Owens Corning OC.N: Barclays raises to overweight from equalweight; raises PT to $245 from $192

* Primoris Services Corp PRIM.N: KeyBanc initiates coverage with overweight rating and $96 target price

* Pultegroup Inc PHM.N: Barclays cuts to equalweight from overweight

* Pultegroup Inc PHM.N: Barclays cuts target price to $140 from $150

* Q32 Bio Inc QTTB.O: Oppenheimer cuts target price to $20 from $80

* Reddit RDDT.N: Baird raises target price to $160 from $100

* Sirius XM Holdings Inc SIRI.O: Benchmark cuts target price to $32 from $43

* Sirius XM Holdings Inc SIRI.O: Seaport Research Partners cuts to neutral from buy

* Smurfit Westrock Plc SW.N: Barclays raises target price to $68 from $60

* Sweetgreen Inc SG.N: KeyBanc initiates coverage with sector weight rating

* Synovus Financial Corp SNV.N: Piper Sandler raises target price to $64 from $56

* Taylor Morrison Home Corp TMHC.N: Barclays raises to overweight from equalweight

* Taylor Morrison Home Corp TMHC.N: Barclays raises target price to $90 from $75

* Transmedics Group Inc TMDX.O: Piper Sandler cuts target price to $90 from $110

* Uniqure NV QURE.O: Leerink Partners raises target price to $44 from $26

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment